CA3258734A1 - COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATE - Google Patents
COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATEInfo
- Publication number
- CA3258734A1 CA3258734A1 CA3258734A CA3258734A CA3258734A1 CA 3258734 A1 CA3258734 A1 CA 3258734A1 CA 3258734 A CA3258734 A CA 3258734A CA 3258734 A CA3258734 A CA 3258734A CA 3258734 A1 CA3258734 A1 CA 3258734A1
- Authority
- CA
- Canada
- Prior art keywords
- methylene
- tetrahydrofolic acid
- pct
- citrate
- lyophilized composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22177932.5 | 2022-06-08 | ||
| EP22177932 | 2022-06-08 | ||
| PCT/EP2023/064972 WO2023237484A1 (en) | 2022-06-08 | 2023-06-05 | Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3258734A1 true CA3258734A1 (en) | 2023-12-14 |
Family
ID=81984853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3258734A Pending CA3258734A1 (en) | 2022-06-08 | 2023-06-05 | COMPOSITIONS CONTAINING 5,10-METHYLENE-(6R)-DISODIC TETRAHYDROFOLATE |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250360135A1 (enExample) |
| EP (1) | EP4536187A1 (enExample) |
| JP (1) | JP2025518274A (enExample) |
| KR (1) | KR20250022145A (enExample) |
| CN (1) | CN119365186A (enExample) |
| AU (1) | AU2023282347A1 (enExample) |
| CA (1) | CA3258734A1 (enExample) |
| IL (1) | IL317395A (enExample) |
| WO (1) | WO2023237484A1 (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3483475D1 (de) | 1983-05-20 | 1990-11-29 | Bengt Gustavsson | Anordnung zur uebertragung einer substanz. |
| CH682664A5 (en) * | 1991-10-15 | 1993-10-29 | Eprova Ag | Stable salts of 5,10-methylene tetrahydrofolate. |
| US5997915A (en) * | 1996-01-31 | 1999-12-07 | South Alabama Medical Science Foundation | Compositions for human and animal consumption containing reduced folates and methods for making and using same |
| CH697021A5 (de) | 2003-06-26 | 2008-03-31 | Merck Eprova Ag | Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat. |
| KR20080074201A (ko) | 2005-12-02 | 2008-08-12 | 어드벤트륵스 파마슈티칼스, 인크. | 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물 |
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| US10059710B2 (en) | 2016-02-17 | 2018-08-28 | Merck & Cie | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid |
| DK3668516T3 (da) | 2017-08-16 | 2021-12-13 | Merck Patent Gmbh | Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre |
| CN107892692A (zh) * | 2017-12-28 | 2018-04-10 | 华东理工大学 | (6s)‑5‑甲基四氢叶酸锌盐的制备方法及其应用 |
-
2023
- 2023-06-05 KR KR1020257000562A patent/KR20250022145A/ko active Pending
- 2023-06-05 CA CA3258734A patent/CA3258734A1/en active Pending
- 2023-06-05 AU AU2023282347A patent/AU2023282347A1/en active Pending
- 2023-06-05 EP EP23730517.2A patent/EP4536187A1/en active Pending
- 2023-06-05 JP JP2024570947A patent/JP2025518274A/ja active Pending
- 2023-06-05 WO PCT/EP2023/064972 patent/WO2023237484A1/en not_active Ceased
- 2023-06-05 CN CN202380045351.1A patent/CN119365186A/zh active Pending
- 2023-06-05 IL IL317395A patent/IL317395A/en unknown
- 2023-06-05 US US18/872,672 patent/US20250360135A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4536187A1 (en) | 2025-04-16 |
| IL317395A (en) | 2025-02-01 |
| KR20250022145A (ko) | 2025-02-14 |
| CN119365186A (zh) | 2025-01-24 |
| AU2023282347A1 (en) | 2025-01-16 |
| JP2025518274A (ja) | 2025-06-12 |
| US20250360135A1 (en) | 2025-11-27 |
| WO2023237484A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2991619B1 (en) | Stable pharmaceutical composition containing folates | |
| US20160030573A1 (en) | Stable pharmaceutical compositions of 5,10-methylenetetrahydrofolate | |
| US20090325978A1 (en) | Stable lyophilized preparation | |
| BG65827B1 (bg) | Фармацевтични разтвори от левосимендан | |
| US9301922B1 (en) | Stable high strength pharmaceutical composition of levoleucovorin | |
| US20090221594A1 (en) | Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolate | |
| US20250360135A1 (en) | Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate | |
| US20250319022A1 (en) | Concentrated solutions comprising sodium 5,10-methylene-(6r)-tetrahydrofolate | |
| US20060063833A1 (en) | Ready-to-use oxaliplatin solutions | |
| US20070276008A1 (en) | Pharmaceutical formulation comprising glycine as a stabilizer | |
| US20250319089A1 (en) | Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid | |
| US20220151923A1 (en) | Stable liquid compositions of pemetrexed | |
| EP1039905B1 (en) | Pharmaceutical formulation comprising glycine as a stabilizer | |
| US20260000671A1 (en) | Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid | |
| WO2023237483A1 (en) | Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid | |
| CA3258607A1 (en) | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID AND NACL | |
| WO2025165852A1 (en) | Liquid formulations of lurbinectedin |